Generate Biomedicines Signs Zealand Pharma Collaboration Worth Up to Nearly $1.2 Billion
Generate Biomedicines will design AI-engineered protein therapeutics for metabolic diseases with Zealand Pharma. The deal includes $30 million upfront, up to $35 million in early preclinical milestones, and eligibility for nearly $1.2 billion in total milestones plus tiered royalties.
Generate Biomedicines and Zealand Pharma will work together to design AI-engineered protein therapeutics for metabolic diseases. 2B in total milestones, plus tiered royalties.